Biogen Inc (BIIB.O) 202Q6 call takeaways: Commercial momentum improves, but pipeline execution remains key

Research evidence excerpt

Biogen Inc (BIIB.O) 202Q6 call takeaways: Commercial momentum improves, but pipeline execution remains key

Flash |

29 Jul 2026 12:12:05 ET │ 11 pages

Biogen Inc (BIIB.O)

2Q26 call takeaways: Commercial momentum improves, but pipeline

execution remains key

CITI'S TAKE Neutral

Price (28 Jul 26 16:00) US$205.61 Interest in the Biogen story is beginning to broaden from the late-stage

Target price US$200.00 pipeline toward improving commercial execution, with faster-than-

expected Spinraza HD conversion helping reinvigorate the SMA franchise Expected share price return -2.7%

and supporting the raised 2026 outlook. New patient starts and switch- Expected dividend yield 0.0%

backs from Roche's Evrysdi appear particularly encouraging for franchise Expected total return -2.7%

durability, while Leqembi IQLIK (SC formulation for Alzheimer's) could Market Cap US$30,356M

lower barriers to treatment initiation and eventually capture Lilly's Kisunla

patients completing therapy. The Apellis acquisition adds a more

immediate growth layer through Syfovre and Empaveli, with Biogen’s

commercialization capabilities offering opportunities to improve uptake Geoff Meacham, Ph.D.AC

and persistence into expected non-GAAP diluted EPS accretion in 2027. +1-404-443-4701

Still, sustaining a more durable reacceleration will likely require successful geoffrey.meacham@citi.com

pipeline execution, with five phase 3 readouts by YE27 (more below). We Jarwei Fang

believe investors remain cautious on litifilimab in SLE, while greater +1-212-816-5127

optimism around felzartamab still needs to be validated by late-stage jarwei.fang@citi.com

data. Maintain Neutral and $200 TP.

Nishant Gandhi, Ph.D.

nishant.gandhi@citi.com

Spinraza HD is reinvigorating the SMA franchise — Spinraza HD conversion is